4.8 Article

Ribosomal protein S11 influences glioma response to TOP2 poisons

Journal

ONCOGENE
Volume 39, Issue 27, Pages 5068-5081

Publisher

SPRINGERNATURE
DOI: 10.1038/s41388-020-1342-0

Keywords

-

Funding

  1. SPORE for Translational Approaches to Brain Cancer [5DP5OD021356-05, P50CA221747]
  2. Robert H. Lurie NCI Cancer Center Support Grant [P30CA060553]
  3. NCI CCSG [P30 CA060553]
  4. NVKP [16-1-2016-0037]

Ask authors/readers for more resources

Topoisomerase II poisons are one of the most common class of chemotherapeutics used in cancer. We and others had shown that a subset of glioblastomas, the most malignant of all primary brain tumors in adults, is responsive to TOP2 poisons. To identify genes that confer susceptibility to this drug in gliomas, we performed a genome-scale CRISPR knockout screen with etoposide. Genes involved in protein synthesis and DNA damage were implicated in etoposide susceptibility. To define potential biomarkers for TOP2 poisons, CRISPR hits were overlapped with genes whose expression correlates with susceptibility to this drug across glioma cell lines, revealing ribosomal protein subunit RPS11, 16, and 18 as putative biomarkers for response to TOP2 poisons. Loss of RPS11 led to resistance to etoposide and doxorubicin and impaired the induction of proapoptotic gene APAF1 following treatment. The expression of these ribosomal subunits was also associated with susceptibility to TOP2 poisons across cell lines from gliomas and multiple other cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available